PMID- 34490702
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 11
DP  - 2021 Nov
TI  - Association between alpha-glucosidase inhibitor use and psoriatic disease risk in 
      patients with type 2 diabetes mellitus: A population-based cohort study.
PG  - e14819
LID - 10.1111/ijcp.14819 [doi]
AB  - AIMS: To investigate the association between the use of alpha-glucosidase 
      inhibitors (AGIs) and the risk of psoriatic disease (ie, psoriasis and psoriatic 
      arthritis) in patients with type 2 diabetes mellitus (T2DM) treated with 
      metformin. METHODS: Using the 1999-2013 Taiwanese Longitudinal Cohort of Diabetes 
      Patients Database, we identified patients with T2DM who initiated hypoglycaemic 
      treatment between 2003 and 2012. After excluding patients with a history of 
      psoriatic disease (International Classification of Disease, Ninth Revision, 
      Clinical Modification codes 696.0-1) before T2DM diagnosis, patients who received 
      antidiabetic treatment for <90 days, and patients aged <20 or >100 years, we 
      identified 1390 patients who received metformin+AGIs (AGI exposure group) and 
      47 514 patients who received metformin only (comparison group). We matched the 
      two groups at a 1:10 ratio by age, sex, and index date of T2DM drug use. The 
      association between AGI use and psoriatic disease risk was analysed using a Cox 
      proportional hazard mode; time-dependent covariates for factors were reported in 
      terms of hazard ratios (HRs) with 95% confidence intervals (CIs) after age, sex, 
      T2DM duration, and comorbidities were controlled for. RESULTS: After adjusting 
      the AGI exposure and comparison groups for potential confounders, we found that 
      psoriatic disease risk was associated with metformin+AGI use when AGI was 
      discontinued for 30 days (HR, 8.77; 95% CI, 1.58-48.5) and when a high AGI dose 
      was administered; furthermore, the risk declined during AGI discontinuation. 
      CONCLUSIONS: This population-based study reports that AGI use and interruption of 
      AGI use may be associated with increased psoriatic disease risk in treated 
      patients with T2DM.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Huang, Pei-Ju
AU  - Huang PJ
AD  - Institute of Medicine, College of Medicine, Chung Shan Medical University, 
      Taichung, Taiwan.
AD  - Department of Family Medicine, Changhua Christian Hospital, Changhua, Taiwan.
FAU - Wei, James Cheng-Chung
AU  - Wei JC
AD  - Institute of Medicine, College of Medicine, Chung Shan Medical University, 
      Taichung, Taiwan.
AD  - Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University 
      Hospital, Taichung, Taiwan.
AD  - Graduate Institute of Integrated Medicine, China Medical University, Taichung, 
      Taiwan.
FAU - Liu, Yen-Tze
AU  - Liu YT
AD  - Institute of Medicine, College of Medicine, Chung Shan Medical University, 
      Taichung, Taiwan.
AD  - Department of Family Medicine, Changhua Christian Hospital, Changhua, Taiwan.
AD  - Department of Holistic Wellness, Mingdao University, Changhua, Taiwan.
FAU - Lin, Ching-Heng
AU  - Lin CH
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung, 
      Taiwan.
AD  - Department of Healthcare Management, National Taipei University of Nursing and 
      Health Sciences, Taipei, Taiwan.
AD  - Department of Industrial Engineering and Enterprise Information, Tunghai 
      University, Taichung, Taiwan.
FAU - Lin, Chi-Chien
AU  - Lin CC
AD  - Institute of Biomedical Science and Rong Hsing Research Centre for Translational 
      Medicine, Chung Hsing University, Taichung, Taiwan.
AD  - Department of Medical Research, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Chen, Hsin-Hua
AU  - Chen HH
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung, 
      Taiwan.
AD  - Department of Industrial Engineering and Enterprise Information, Tunghai 
      University, Taichung, Taiwan.
AD  - Institute of Biomedical Science and Rong Hsing Research Centre for Translational 
      Medicine, Chung Hsing University, Taichung, Taiwan.
AD  - Department of Medical Research, China Medical University Hospital, Taichung, 
      Taiwan.
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
AD  - Institute of Public Health and Community Medicine Research Centre, National 
      Yang-Ming University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20210916
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Glycoside Hydrolase Inhibitors/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - *Metformin/adverse effects
EDAT- 2021/09/08 06:00
MHDA- 2023/02/25 06:00
CRDT- 2021/09/07 08:02
PHST- 2021/04/23 00:00 [received]
PHST- 2021/09/03 00:00 [accepted]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2021/09/07 08:02 [entrez]
AID - 10.1111/ijcp.14819 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Nov;75(11):e14819. doi: 10.1111/ijcp.14819. Epub 2021 Sep 
      16.